DOCEFREZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOCEFREZ (DOCEFREZ).
Docetaxel binds to beta-tubulin, promoting microtubule assembly and inhibiting depolymerization, resulting in cell cycle arrest at G2/M phase and apoptosis.
| Metabolism | Hepatic metabolism via CYP3A4/5; biliary excretion. |
| Excretion | Primarily renal excretion (70-80% as unchanged drug) with hepatic metabolism contributing to biliary/fecal elimination (20-30%). |
| Half-life | Terminal elimination half-life is 4.5-6.0 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound primarily to albumin. |
| Volume of Distribution | 0.6 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is 65-75% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Intravenous: onset within 5-10 minutes; Oral: onset within 30-60 minutes. |
| Duration of Action | 4-6 hours for intravenous administration; 6-8 hours for oral administration, depending on dose and renal function. |
| Molecular Weight | 861.92 |
| Action Class | Antimicrotubule agents- Taxanes |
| Brand Substitutes | Docax 80mg Injection, Relidoce 80mg Injection, Chemodoc 80mg Injection, Zenotere 80mg Injection, Innotubilin 80mg Injection |
75 mg/m² intravenously over 1 hour every 3 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) due to potential toxicity. |
| Liver impairment | For Child-Pugh A (total bilirubin ≤1.5× ULN and AST/ALT ≤2.5× ULN): 75 mg/m². For Child-Pugh B (total bilirubin 1.6-3.0× ULN or AST/ALT 2.6-5.0× ULN): reduce dose to 25 mg/m². Child-Pugh C: not recommended. |
| Pediatric use | In pediatric patients (≥2 years), 50 mg/m² intravenously over 1 hour every 3 weeks. Dose reduction to 35 mg/m² for poor performance status or prior extensive therapy. |
| Geriatric use | No specific dose adjustment required in elderly patients with normal hepatic function. Monitor for increased myelosuppression, neuropathy, and fatigue. |
| 1st trimester | DOCEFREZ is a docetaxel formulation. Contraindicated in first trimester due to high risk of embryofetal toxicity, including malformations and spontaneous abortion. |
| 2nd trimester | Contraindicated. Fetal harm is expected; avoid use unless benefit outweighs risk in life-threatening conditions. |
| 3rd trimester | Contraindicated near term due to risk of neonatal myelosuppression and infection. |
Clinical note
Comprehensive clinical and safety monograph for DOCEFREZ (DOCEFREZ).
| Placental transfer | Docetaxel actively crosses the placenta; fetal plasma concentrations can reach maternal levels. Animal studies show embryotoxicity and fetotoxicity. |
| Breastfeeding | Docetaxel is excreted into human milk in low concentrations. Due to potential serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 2 weeks after last dose. |
■ FDA Black Box Warning
Toxic deaths: Increased mortality in patients with elevated liver function tests, low performance status, or receiving higher doses; Neutropenia: Severe neutropenia with risk of infection; Hypersensitivity reactions: Severe reactions require immediate discontinuation; Fluid retention: Severe fluid retention despite premedication.
| Serious Effects |
PregnancyBreastfeedingSevere hypersensitivity to docetaxel or polysorbate 80Baseline neutrophil count <1500 cells/mm³
| Precautions | Bone marrow suppression (neutropenia, febrile neutropenia), hypersensitivity reactions, fluid retention, hepatotoxicity, neurotoxicity, severe cutaneous reactions, and drug interactions with CYP3A4 inhibitors/inducers. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase docetaxel levels via CYP3A4 inhibition. No other significant food interactions reported. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: associated with increased risk of neural tube defects, cardiac anomalies, and oral clefts. Second and third trimesters: risk of preterm birth, low birth weight, and neonatal hemorrhage. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal hepatic function (AST, ALT, bilirubin), renal function (serum creatinine, BUN), complete blood count with differential, and coagulation profile. Fetal monitoring includes serial ultrasound for growth and amniotic fluid volume, and nonstress testing or biophysical profile after 28 weeks. |
| Fertility Effects | May impair fertility in both males and females. Reversible oligospermia and reduced sperm motility reported in males. Females may experience menstrual irregularities and anovulation. |
| Clinical Pearls | Monitor for infusion reactions, especially during first and second doses; premedicate with corticosteroids, antihistamines, and H2 antagonists. Use non-DEHP plasticized containers and polyethylene-lined administration sets due to leaching of DEHP. Administer through an in-line filter of 0.22 microns. Do not use with cisplatin due to increased nephrotoxicity. |
| Patient Advice | Report any signs of infusion reaction such as flushing, chest tightness, or difficulty breathing immediately. · You may experience hair loss, which is temporary. · Avoid grapefruit and grapefruit juice during treatment as it may affect drug levels. · Use effective contraception during and for at least 3 months after treatment. · Contact your healthcare provider if you experience fever, chills, sore throat, or unusual bleeding/bruising. |